サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1409032

感染症診断の世界市場：製品・サービス別、検査タイプ別、標本別、技術別、疾患別 - 予測（～2028年）

Infectious Disease Diagnostics Market by Product & Service, Test Type, Sample, Technology, Disease - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 303 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
感染症診断の世界市場：製品・サービス別、検査タイプ別、標本別、技術別、疾患別 - 予測（～2028年）
出版日: 2024年01月09日
発行: MarketsandMarkets
ページ情報: 英文 303 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

レポートの概要

調査範囲
調査対象年 2021年～2028年
基準年 2022年
予測期間 2023年～2028年
単位 10億米ドル
セグメント 製品サービス、検査タイプ、標本タイプ、技術、疾患タイプ、エンドユーザー
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

世界の感染症診断の市場規模は、2023年に214億米ドル、2028年までに315億米ドルに達し、CAGRで8.0%の成長が予測されています。

分散型診断への注目の高まりとCLIA免除PoC検査への需要の増加が、PoC技術の利用を促進しています。感染症診断市場における分散型PoC検査の動向は、より効率的な医療提供へのニーズによってさらに後押しされています。集中型検査施設は、特に遠隔地や十分なサービスを受けていない地域において、納期の長期化やロジスティクスの複雑化といった課題に直面することが多いです。ポイントオブケア環境への検査の分散化により、医療従事者は患者のそばで診断ができるようになり、標本の採取から結果の報告までの時間が短縮されます。このパラダイムシフトは、タイムリーな患者ケアを支援するだけでなく、感染症の迅速な特定と封じ込めを助け、ひいては公衆衛生の改善に寄与します。

「検査タイプ別では、PoC検査セグメントが予測期間に市場でもっとも高い成長率を占めました。」

感染症診断市場は臨床検査とPoC検査に二分されます。市場のPoC検査セグメントは大きな成長を示しています。PoC検査セグメントの成長は、製品の発売や買収といった新たな開発への注力を含む、多くの企業による投資によって後押しされています。病院や診療所で臨床検査ではなくPoC検査を使用する大きな利点の1つは、臨床検査よりも検査までの所要時間が短いことです。さらに、PoC検査は従来の臨床検査よりも少ない標本量で済みます。このように、患者の状態を注意深くモニターする必要性と、より速い診断速度などの利点が、PoC検査の需要を促進する大きな要因です。

「技術別では、DNAシーケンシング・次世代シーケンシングセグメントが予測期間に市場でもっとも高い成長率を占めました。」

DNAシーケンシング・次世代シーケンシングセグメントは、予測期間にもっとも高いCAGRを占めると予測されます。DNAシーケンシングは、迅速な結果に向けて診療所で直接セットアップできる扱いやすいプラットフォームです。DNAシーケンシングの能力は、個別化医療、がん研究、創薬、農業、動物科学など、さまざまな研究セグメントでの応用の機会を開いています。シーケンシング技術の進歩、シーケンシング技術の幅広い用途、個別化医療に対する需要の高まりなどの要因が、今後数年間の市場成長を支える要因になると予測されます。

「アジア太平洋：最速で成長している地域市場」

アジア太平洋市場は予測期間にもっとも高い成長が見込まれます。この地域の新興国はGDPの成長と可処分所得水準の大幅な向上を示しています。これが、より多くの人々による医療支出の増加につながっています。その他、アジア太平洋諸国における感染症の罹患率および有病率の増加や、医療インフラの近代化、最先端技術の浸透（特に農村部）なども、同地域の感染症診断企業に大きな成長機会をもたらすと予測されます。

当レポートでは、世界の感染症診断市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 感染症診断市場の概要
  • 感染症診断市場：製品/サービス別（2023年・2028年）
  • 感染症診断市場：検査タイプ別（2023年・2028年）
  • 感染症診断市場：標本タイプ別（2023年・2028年）
  • 感染症診断市場：技術別（2023年・2028年）
  • 感染症診断市場：疾患タイプ別（2023年・2028年）
  • 感染症診断市場：エンドユーザー別（2023年・2028年）
  • 地域の成長機会

第5章 市場の概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 価格分析
  • 特許分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム市場マップ
  • ポーターのファイブフォース分析
  • 規制情勢
    • 規制機関、政府機関、その他の組織
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東
  • 貿易分析
  • 技術分析
  • 主な会議とイベント
  • 顧客のビジネスに影響を与える動向/混乱
  • 主なステークホルダーと購入基準
  • ケーススタディ分析

第6章 感染症診断市場：製品/サービス別

  • イントロダクション
  • 試薬、キット、消耗品
  • 器具
  • ソフトウェア・サービス

第7章 感染症診断市場：検査タイプ別

  • イントロダクション
  • 臨床検査
  • PoC検査

第8章 感染症診断市場：標本タイプ別

  • イントロダクション
  • 血液、血清、血漿
  • 尿
  • その他の標本タイプ

第9章 感染症診断市場：疾患別

  • イントロダクション
  • 肝炎
    • B型肝炎
    • C型肝炎
    • その他の肝炎疾患
  • HIV
  • 院内感染
  • 蚊媒介感染症
  • HPV
  • クラミジア感染症
  • 淋菌
  • 結核
  • インフルエンザ
  • 梅毒
  • その他の感染症
  • COVID-19

第10章 感染症診断市場：技術別

  • イントロダクション
  • 主なメモ
  • 免疫診断
  • 臨床微生物学
  • ポリメラーゼ連鎖反応
  • 等温核酸増幅技術
  • DNAシーケンシング・次世代シーケンシング
  • DNAマイクロアレイ
  • その他の技術

第11章 感染症診断市場：エンドユーザー別

  • イントロダクション
  • 診断研究所
  • 病院・診療所
  • 学術研究機関
  • その他のエンドユーザー

第12章 感染症診断市場：地域別

  • イントロダクション
  • 北米
    • 北米の不況の影響
    • 米国
    • カナダ
  • 欧州
    • 欧州の不況の影響
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • アジア太平洋の不況の影響
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
    • 中東・アフリカの不況の影響
    • GCC諸国
    • その他の中東・アフリカ

第13章 競合情勢

  • 概要
  • 主な戦略/有力企業
  • 収益シェア分析
  • 市場シェア分析
  • 企業の評価マトリクス
  • スタートアップ/中小企業の評価マトリクス
  • 競合シナリオと動向

第14章 企業プロファイル

  • 主要企業
    • F. HOFFMANN-LA ROCHE LTD.
    • ABBOTT
    • BIOMERIEUX
    • SIEMENS HEALTHINEERS AG
    • DANAHER
    • THERMO FISHER SCIENTIFIC INC.
    • HOLOGIC, INC.
    • BECTON, DICKINSON AND COMPANY
    • REVVITY
    • QIAGEN
    • SEEGENE INC.
  • その他の企業
    • QUIDELORTHO CORPORATION
    • GRIFOLS, S.A.
    • DIASORIN S.P.A.
    • BIO-RAD LABORATORIES, INC.
    • SYSMEX CORPORATION
    • ORASURE TECHNOLOGIES
    • CO-DIAGNOSTICS, INC.
    • MERIDIAN BIOSCIENCE
    • CHEMBIO DIAGNOSTICS, INC.
    • TRINITY BIOTECH
    • GENETIC SIGNATURES LTD.
    • EPITOPE DIAGNOSTICS, INC.
    • TRIVITRON HEALTHCARE
    • ELITECH GROUP
    • MERIL LIFE SCIENCES PVT. LTD.
    • INBIOS INTERNATIONAL, INC.
    • UNIOGEN OY
    • VELA DIAGNOSTICS

第15章 付録

目次
Product Code: MD 3088

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsProduct & Service, Type of Testing, Sample Type, Technology, Disease Type, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

The infectious disease diagnostics market is valued at an estimated USD 21.4 billion in 2023 and is projected to reach USD 31.5 billion by 2028 at a CAGR of 8.0% during the forecast period. The rising focus on decentralized diagnostics and the growing demand for CLIA-waived PoC tests have driven the use of PoC technologies. The trend towards decentralized PoC testing in the infectious disease diagnostics market is further fueled by the need for more efficient healthcare delivery. Centralized laboratories often face challenges such as longer turnaround times and logistical complexities, particularly in remote or underserved areas. The decentralization of testing to point-of-care settings empowers healthcare professionals with the ability to conduct diagnostics at the patient's side, reducing the time between sample collection and result delivery. This paradigm shift not only supports timely patient care but also aids in the prompt identification and containment of infectious diseases, ultimately contributing to improved public health outcomes.

"PoC testing segment accounted for the highest growth rate in the infectious disease diagnostics market, by type of testing, during the forecast period."

The infectious disease diagnostics market is bifurcated into laboratory testing and PoC testing. The PoC testing segment in the infectious disease diagnostics market is experiencing substantial growth. The growth of the PoC segment is being fueled by the investments made by numerous companies, including their focus on new developments such as product launches and acquisitions. One of the main advantages of using PoC testing in hospitals or clinics over laboratory tests is that they have a faster turnaround time for testing than laboratory tests. Additionally, PoC testing requires lower sample volumes than traditional laboratory tests. Thus, the need to closely monitor patient conditions and advantages such as a faster diagnosis rate are the major factors driving the demand for PoC tests.

"DNA sequencing & next-generation sequencing segment accounted for the highest growth rate in the infectious disease diagnostics market, by technology, during the forecast period."

The infectious disease diagnostics market is bifurcated into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies based on technology. DNA sequencing & next-generation sequencing segment is expected to account for the highest CAGR during the forecast period. DNA sequencing is an easy platform that can be set up directly in the clinic for quick results. The ability to sequence DNA has opened opportunities for applications in various research fields, such as personalized medicine, cancer research, drug discovery, and agricultural and animal sciences. Factors such as advancements in sequencing technologies, a wide range of applications of sequencing technologies, and the growing demand for personalized medicine are factors expected to support market growth in the coming years.

"Asia Pacific: The fastest-growing region infectious disease diagnostics market"

The global infectious disease diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period. Emerging countries in this region are witnessing growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base. Other factors such as the increasing incidence & prevalence of infectious diseases, healthcare infrastructure modernization, and the rising penetration of cutting-edge technologies (especially in rural areas) in Asia Pacific countries are also expected to provide significant growth opportunities for infectious disease diagnostics companies in this region.

The break-up of the profile of primary participants in the infectious disease diagnostics market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Siemens Healthineers AG (Germany), Danaher (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Revvity (US), QIAGEN (Netherlands), Seegene Inc. (South Korea), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QuidelOrtho Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech (Ireland), Chembio Diagnostics, Inc. (US), Co-Diagnostics, Inc. (US), ELITech Group (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Vela Diagnostics (Singapore), and Uniogen Oy (Finland).

Research Coverage:

This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, dna sequencing & next-generation sequencing, dna microarray, and other technologies), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the infectious disease diagnostics market. Competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising prevalence of infectious diseases, Rising focus on R&D and funding in infectious disease diagnostic products, Growing awareness for early disease diagnosis in emerging economies, Adoption of new and advanced technologies for infectious disease diagnosis, Shift in focus from centralized laboratories to decentralized PoC testing centers), opportunities (Increased growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (Changing regulatory landscape, Operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the infectious disease diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Siemens Healthineers AG (Germany), Danaher (US), and Thermo Fisher Scientific Inc. (US), among others in the infectious disease diagnostics market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 MARKETS COVERED
    • 1.4.2 REGIONS COVERED
    • 1.4.3 YEARS CONSIDERED
    • 1.4.4 CURRENCY CONSIDERED
  • 1.5 RESEARCH LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.2.2.1 Key data from primary sources
    • 2.2.3 KEY INDUSTRY INSIGHTS
      • 2.2.3.1 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.2 COMPANY REVENUE ESTIMATION APPROACH
    • FIGURE 5 COMPANY REVENUE ESTIMATION APPROACH: INFECTIOUS DISEASE DIAGNOSTICS MARKET
    • 2.3.3 PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
    • 2.3.4 GROWTH FORECAST
    • 2.3.5 CAGR PROJECTIONS
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.6 TOP-DOWN APPROACH
    • FIGURE 7 TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ASSESSMENT
  • 2.6 STUDY ASSUMPTIONS
    • 2.6.1 GROWTH RATE ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 2.8 IMPACT OF RECESSION ON INFECTIOUS DISEASE DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 16 GROWING PREVALENCE OF INFECTIOUS DISEASE AND INCREASING INVESTMENT IN R&D TO DRIVE MARKET
  • 4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION)
    • FIGURE 18 LABORATORY TESTING TO DOMINATE MARKET DURING STUDY PERIOD
  • 4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 19 BLOOD, SERUM, AND PLASMA TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
  • 4.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 20 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 21 HEPATITIS TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
  • 4.7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 22 DIAGNOSTIC LABORATORIES TO DOMINATE MARKET DURING STUDY PERIOD
  • 4.8 REGIONAL GROWTH OPPORTUNITIES
    • FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: INFECTIOUS DISEASE DIAGNOSTICS MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of infectious diseases
      • 5.2.1.2 Rising focus on R&D and funding for infectious disease diagnostic products
      • 5.2.1.3 Growing awareness for early disease diagnosis in emerging economies
      • 5.2.1.4 Adoption of new and advanced technologies for infectious disease diagnosis
      • 5.2.1.5 Shift in focus from centralized laboratories to decentralized PoC testing centers
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape
      • 5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
  • 5.3 PRICING ANALYSIS
    • TABLE 2 INDICATIVE PRICING FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    • TABLE 3 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION
  • 5.4 PATENT ANALYSIS
    • FIGURE 25 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013-DECEMBER 2022)
    • TABLE 4 LIST OF MAJOR PATENTS, JANUARY 2021-DECEMBER 2022
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 27 SUPPLY CHAIN ANALYSIS: INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.7 ECOSYSTEM MARKET MAP
    • FIGURE 28 ECOSYSTEM MARKET MAP: INFECTIOUS DISEASE DIAGNOSTICS MARKET
    • TABLE 5 ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY LANDSCAPE
    • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.2 NORTH AMERICA
      • 5.9.2.1 US
      • 5.9.2.2 Canada
    • 5.9.3 EUROPE
    • TABLE 11 EUROPE: CLASSIFICATION OF DEVICES
    • 5.9.4 ASIA PACIFIC
      • 5.9.4.1 China
      • 5.9.4.2 Japan
    • TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.4.3 India
    • 5.9.5 LATIN AMERICA
      • 5.9.5.1 Brazil
      • 5.9.5.2 Mexico
    • 5.9.6 MIDDLE EAST
      • 5.9.6.1 Africa
  • 5.10 TRADE ANALYSIS
    • TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.11 TECHNOLOGY ANALYSIS
  • 5.12 KEY CONFERENCES & EVENTS
    • TABLE 15 DETAILED LIST OF KEY CONFERENCES & EVENTS IN 2O22-2023
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 29 REVENUE SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
    • 5.14.2 BUYING CRITERIA
    • FIGURE 31 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    • TABLE 17 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
  • 5.15 CASE STUDY ANALYSIS
    • FIGURE 32 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 19 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2022
  • 6.2 REAGENTS, KITS, AND CONSUMABLES
    • 6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO DRIVE MARKET
    • TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS WITH MINIMUM HUMAN INTERVENTION TO DRIVE MARKET
    • TABLE 21 KEY INSTRUMENTS AVAILABLE IN MARKET
    • TABLE 22 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS AND INCREASING COMPETITIVENESS FOR VALUE-ADDED SERVICES TO DRIVE MARKET
    • TABLE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING

  • 7.1 INTRODUCTION
    • TABLE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2021-2028 (USD MILLION)
    • 7.1.1 PRIMARY NOTES
    • FIGURE 33 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING
  • 7.2 LABORATORY TESTING
    • 7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
    • TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 POC TESTING
    • 7.3.1 FASTER TURNAROUND TIME AND MORE EFFICIENT TREATMENT OPTIONS TO DRIVE MARKET
    • TABLE 26 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2021-2028 (USD MILLION)

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE

  • 8.1 INTRODUCTION
    • TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • 8.1.1 PRIMARY NOTES
    • FIGURE 34 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE
  • 8.2 BLOOD, SERUM, AND PLASMA
    • 8.2.1 HIGHER VERSATILITY, GREATER CLINICAL EFFICACY, AND BETTER REIMBURSEMENT POLICIES TO DRIVE MARKET
    • TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 URINE
    • 8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO DRIVE MARKET
    • TABLE 29 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 OTHER SAMPLE TYPES
    • TABLE 30 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE

  • 9.1 INTRODUCTION
    • TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
  • 9.2 HEPATITIS
    • TABLE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021-2028 (MILLION TESTS)
    • TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2021-2028 (USD MILLION)
    • TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.2.1 HEPATITIS B
      • 9.2.1.1 Increasing global prevalence of hepatitis B to drive segment
    • TABLE 36 HEPATITIS B MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 9.2.2 HEPATITIS C
      • 9.2.2.1 Rising number of government initiatives for hepatitis C diagnosis to drive segment
    • TABLE 37 HEPATITIS C MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 9.2.3 OTHER HEPATITIS DISEASES
    • TABLE 38 OTHER HEPATITIS DISEASES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 HIV
    • 9.3.1 GROWING PREVALENCE OF AIDS AND INCREASING AVAILABILITY OF HIV POC TESTING TO DRIVE MARKET
    • TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2021-2028 (MILLION TESTS)
  • 9.4 HOSPITAL-ACQUIRED INFECTIONS
    • 9.4.1 RISING BURDEN OF INFECTIONS AND INCREASING ADOPTION OF ADVANCED DIAGNOSTIC TESTS TO DRIVE MARKET
    • TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 42 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2028 (MILLION TESTS)
  • 9.5 MOSQUITO-BORNE DISEASES
    • 9.5.1 RISING INCIDENCE OF DENGUE AND MALARIA AND INCREASING NUMBER OF AWARENESS PROGRAMS TO DRIVE MARKET
    • TABLE 43 MAJOR PRODUCTS FOR DENGUE TESTING AVAILABLE IN MARKET
    • TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2021-2028 (USD MILLION)
  • 9.6 HPV
    • 9.6.1 TECHNOLOGICAL ADVANCEMENTS FOR PREVENTING HPV INFECTIONS TO DRIVE MARKET
    • TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 46 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2021-2028 (MILLION TESTS)
  • 9.7 CHLAMYDIA TRACHOMATIS
    • 9.7.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET
    • TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021-2028 (MILLION TESTS)
  • 9.8 NEISSERIA GONORRHEA
    • 9.8.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET
    • TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA, BY REGION, 2021-2028 (USD MILLION)
  • 9.9 TUBERCULOSIS
    • 9.9.1 INCREASING BURDEN OF TUBERCULOSIS IN UNDERDEVELOPED NATIONS TO DRIVE MARKET
    • TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021-2028 (MILLION TESTS)
    • TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY METHOD, 2021-2028 (USD MILLION)
  • 9.10 INFLUENZA
    • 9.10.1 RISING FOCUS ON FASTER DIAGNOSIS AND CONTROL TO DRIVE MARKET
    • TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2021-2028 (MILLION TESTS)
    • TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2021-2028 (USD MILLION)
  • 9.11 SYPHILIS
    • 9.11.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES FOR IMPROVED SCREENING TO DRIVE MARKET
    • TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2021-2028 (USD MILLION)
  • 9.12 OTHER INFECTIOUS DISEASES
    • TABLE 57 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
  • 9.13 COVID-19
    • 9.13.1 DECLINING CASES OF COVID-19 TO LIMIT MARKET
    • TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION)

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 10.1 INTRODUCTION
  • 10.2 PRIMARY NOTES
    • FIGURE 35 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY
    • TABLE 59 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 10.3 IMMUNODIAGNOSTICS
    • 10.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
    • TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
  • 10.4 CLINICAL MICROBIOLOGY
    • 10.4.1 QUICKER TURNAROUND TIME FOR RESULTS WITH HIGHER SENSITIVITY AND RELIABILITY TO DRIVE MARKET
    • TABLE 61 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 10.5 POLYMERASE CHAIN REACTION
    • 10.5.1 EASE OF USE, COST-EFFECTIVENESS, AND HIGH SPECIFICITY TO DRIVE MARKET
    • TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021-2028 (USD MILLION)
  • 10.6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • 10.6.1 LOWER COST AND BETTER SUITABILITY FOR POINT-OF-CARE TESTING TO DRIVE MARKET
    • TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 10.7 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
    • 10.7.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND INCREASED FOCUS ON MOLECULAR TARGETED DRUGS TO DRIVE MARKET
    • TABLE 64 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
  • 10.8 DNA MICROARRAY
    • 10.8.1 HIGH INSTRUMENT COSTS AND NEED FOR EXPERT TECHNICIANS TO LIMIT MARKET
    • TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2021-2028 (USD MILLION)
  • 10.9 OTHER TECHNOLOGIES
    • TABLE 66 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2 DIAGNOSTIC LABORATORIES
    • 11.2.1 DEVELOPMENT OF LOW-COST AND HIGHLY SPECIALIZED SCREENING TESTS TO DRIVE MARKET
    • TABLE 68 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 11.3 HOSPITALS & CLINICS
    • 11.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND BETTER REIMBURSEMENT FACILITIES TO DRIVE MARKET
    • TABLE 69 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION)
  • 11.4 ACADEMIC RESEARCH INSTITUTES
    • 11.4.1 INCREASING FOCUS ON R&D FOR DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET
    • TABLE 70 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
  • 11.5 OTHER END USERS
    • TABLE 71 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 72 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 12.2 NORTH AMERICA
    • FIGURE 36 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 73 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 75 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 76 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 77 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.1 NORTH AMERICA: RECESSION IMPACT
    • 12.2.2 US
      • 12.2.2.1 Increasing prevalence of infectious diseases to drive market
    • TABLE 78 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 79 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 80 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.3 CANADA
      • 12.2.3.1 Focus on affordable tests and use of personalized medicine to drive market
    • TABLE 82 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 83 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 84 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3 EUROPE
    • TABLE 86 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 87 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 88 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 90 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.1 EUROPE: RECESSION IMPACT
    • 12.3.2 GERMANY
      • 12.3.2.1 Increasing healthcare expenditure and rising per capita disposable income to drive market
    • TABLE 91 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 92 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 93 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 94 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.3 UK
      • 12.3.3.1 Growing number of accredited diagnostic and hospital laboratories to drive market
    • TABLE 95 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 96 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 97 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 98 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.4 FRANCE
      • 12.3.4.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market
    • TABLE 99 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 100 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 101 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.5 ITALY
      • 12.3.5.1 Increased adoption of advanced diagnostic technologies and growing government healthcare investment to drive market
    • TABLE 103 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 104 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 105 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 106 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.6 SPAIN
      • 12.3.6.1 Rising geriatric population and improving healthcare infrastructure to drive market
    • TABLE 107 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 108 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 109 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 110 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.7 REST OF EUROPE
    • TABLE 111 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)
    • TABLE 112 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 113 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 114 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4 ASIA PACIFIC
    • FIGURE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 116 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 118 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 12.4.2 CHINA
      • 12.4.2.1 Increased public access to modern healthcare and favorable government policies to drive market
    • TABLE 121 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 122 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 123 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 124 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.3 JAPAN
      • 12.4.3.1 Presence of well-developed healthcare system and universal reimbursement policies to drive market
    • TABLE 125 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 126 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 127 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 128 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.4 INDIA
      • 12.4.4.1 Increasing private and public investments in healthcare system to drive market
    • TABLE 129 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 130 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 131 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 132 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.5 REST OF ASIA PACIFIC
    • TABLE 133 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 134 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 135 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.5 LATIN AMERICA
    • 12.5.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET
    • TABLE 137 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 138 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 139 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 140 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.2 LATIN AMERICA: RECESSION IMPACT
  • 12.6 MIDDLE EAST & AFRICA
    • TABLE 141 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 142 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 143 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 144 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 145 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Rising focus on advanced health infrastructure to drive market
    • TABLE 146 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 147 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 148 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.6.3 REST OF MIDDLE EAST & AFRICA
    • TABLE 150 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 151 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 152 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 KEY STRATEGIES/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 154 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 13.3 REVENUE SHARE ANALYSIS
    • FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS
  • 13.4 MARKET SHARE ANALYSIS
    • FIGURE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
    • TABLE 155 DEGREE OF COMPETITION: INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 13.5 COMPANY EVALUATION MATRIX
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • FIGURE 40 COMPANY EVALUATION MATRIX, 2022
    • 13.5.5 COMPANY FOOTPRINT
    • FIGURE 41 PRODUCT AND REGIONAL FOOTPRINT OF KEY PLAYERS
    • TABLE 156 COMPANY FOOTPRINT
    • TABLE 157 PRODUCT & SERVICE FOOTPRINT
    • TABLE 158 REGIONAL FOOTPRINT
  • 13.6 START-UP/SME EVALUATION MATRIX
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • FIGURE 42 START-UP/SME EVALUATION MATRIX, 2022
    • 13.6.5 COMPETITIVE BENCHMARKING
    • TABLE 159 DETAILED LIST OF KEY START-UPS/SMES
  • 13.7 COMPETITIVE SCENARIOS AND TRENDS
    • 13.7.1 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
    • TABLE 160 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS, 2020-2023
    • 13.7.2 KEY DEALS
    • TABLE 161 KEY DEALS, 2020-2023

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 14.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 162 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 14.1.2 ABBOTT
    • TABLE 163 ABBOTT: COMPANY OVERVIEW
    • FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2022)
    • 14.1.3 BIOMERIEUX
    • TABLE 164 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 45 BIOMERIEUX: COMPANY SNAPSHOT (2022)
    • 14.1.4 SIEMENS HEALTHINEERS AG
    • TABLE 165 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
    • FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
    • 14.1.5 DANAHER
    • TABLE 166 DANAHER: COMPANY OVERVIEW
    • FIGURE 47 DANAHER: COMPANY SNAPSHOT (2022)
    • 14.1.6 THERMO FISHER SCIENTIFIC INC.
    • TABLE 167 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 14.1.7 HOLOGIC, INC.
    • TABLE 168 HOLOGIC, INC.: COMPANY OVERVIEW
    • FIGURE 49 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
    • 14.1.8 BECTON, DICKINSON AND COMPANY
    • TABLE 169 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
    • FIGURE 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 14.1.9 REVVITY
    • TABLE 170 REVVITY: COMPANY OVERVIEW
    • FIGURE 51 REVVITY: COMPANY SNAPSHOT (2022)
    • 14.1.10 QIAGEN
    • TABLE 171 QIAGEN: COMPANY OVERVIEW
    • FIGURE 52 QIAGEN: COMPANY SNAPSHOT (2022)
    • 14.1.11 SEEGENE INC.
    • TABLE 172 SEEGENE INC.: COMPANY OVERVIEW
    • FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT (2022)
  • 14.2 OTHER PLAYERS
    • 14.2.1 QUIDELORTHO CORPORATION
    • 14.2.2 GRIFOLS, S.A.
    • 14.2.3 DIASORIN S.P.A.
    • 14.2.4 BIO-RAD LABORATORIES, INC.
    • 14.2.5 SYSMEX CORPORATION
    • 14.2.6 ORASURE TECHNOLOGIES
    • 14.2.7 CO-DIAGNOSTICS, INC.
    • 14.2.8 MERIDIAN BIOSCIENCE
    • 14.2.9 CHEMBIO DIAGNOSTICS, INC.
    • 14.2.10 TRINITY BIOTECH
    • 14.2.11 GENETIC SIGNATURES LTD.
    • 14.2.12 EPITOPE DIAGNOSTICS, INC.
    • 14.2.13 TRIVITRON HEALTHCARE
    • 14.2.14 ELITECH GROUP
    • 14.2.15 MERIL LIFE SCIENCES PVT. LTD.
    • 14.2.16 INBIOS INTERNATIONAL, INC.
    • 14.2.17 UNIOGEN OY
    • 14.2.18 VELA DIAGNOSTICS
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS